SCHRODINGER INC

Company Overview

Schrödinger Inc. (SDGR) operates at the intersection of Healthcare and Health Information Services, selling both hosted/software discovery platforms and partnering with biopharma on drug discovery programs. Q2 2025 revenue was $54.8M (software $40.5M; drug discovery $14.2M), with six‑month revenue up 36% driven by a large Novartis collaboration (a $150M upfront in Jan 2025) and growth in hosted subscriptions. The business mix creates dual drivers: recurring software/subscription metrics and milestone-driven drug discovery payments, while recent cost pressures (personnel, cloud, CRO) have reduced software gross margin and elevated cost of revenues. Management implemented a ~7% headcount restructuring to realize ~ $30M in annualized savings, and clinical progress (e.g., SGR‑11505 Phase 1 data, FDA meeting planned) is a near‑term stock and strategic catalyst. Liquidity is strong (~$462M), but revenue and cash flow remain milestone- and timing-sensitive given the partner/milestone model.

Executive Compensation Practices

Given Schrödinger’s hybrid software-plus-drug-discovery model, executive pay is likely calibrated to both commercial (software ARR, renewals, hosting margins) and R&D/partner milestones (upfronts, milestones, clinical readouts, licensing outcomes). Compensation packages in Health Information Services/Pharmaceutical Products commonly emphasize equity (RSUs/options) over cash to conserve liquidity; at Schrödinger this would align executives’ incentives with long‑term value tied to collaboration milestones (e.g., Novartis payments) and clinical progress (SGR‑11505/2921/3515 readouts). Short‑term bonus metrics may include quarterly/annual revenue growth, margin recovery after elevated cloud/CRO costs, and cost‑savings from the recent restructuring. Boards will likely tie certain bonuses or vesting conditions to milestone recognition, regulatory interactions (FDA meeting outcomes), and cash runway preservation, while retaining standard governance features such as clawbacks and change‑in‑control provisions common in the sector.

Insider Trading Considerations

Insider trading activity at Schrödinger will be highly correlated with milestone and data events: collaboration announcements, upfront/milestone recognitions (Novartis), quarterly results showing margin/cost trends, and clinical data readouts (notably SGR‑11505 Phase 1 updates and upcoming Phase 1 data in Q4 2025). Because the company’s equity‑heavy pay and recent large upfronts create concentrated paper wealth for insiders, expect periodic sales for diversification, often executed under Rule 10b5‑1 plans; conversely purchases by insiders could signal confidence ahead of clinical or partnership milestones. Regulatory risks are elevated versus pure‑software peers since clinical data and partnership negotiations are material non‑public information (MNPI); strict blackout windows, confidentiality clauses in collaboration agreements, and SEC Form 4 reporting rules will govern transactions and increase the informational value of reported insider trades.